Drug intelligence / Profile preview

CP112

Development stage: Preclinical
Lead developer: Consegna Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

CP112 is a preclinical-stage, long-acting injectable small molecule formulation developed by Consegna Pharma for HIV pre-exposure prophylaxis (PrEP). The candidate is designed to provide sustained antiretroviral activity over a 28-day period, aiming to improve adherence and efficacy in preventing the establishment of HIV infection compared to daily oral regimens. It utilizes Consegna's computational drug delivery technology to achieve controlled release of the therapeutic agent.

Other names: HIV PrEP 28-day

Beyond the preview

Go deeper on CP112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP112.

Explore the full profile